Lemonaid Health is a telehealth provider which treats many acute and chronic conditions. It was conducting clinical trials for at-home rapid Covid-19 testing services as of April 2020. The consultation fee is USD 25 (less than the cost of most insurance copays), which covers only the doctor's charge. Some behavioral healthcare services, such as depression and anxiety treatments, charge a flat monthly fee that covers consultations and any medicines that are prescribed. Many consultations happen over the phone, but doctors will switch to video consultation if it's necessary.
In October 2021, D2C genetic testing company 23andMe entered into a definitive merger agreement to acquire Lemonaid Health for a purchase price of USD 400 million. The deal is expected to close by the end of 2021. Following the acquisition, 23andMe plans to offer genetic testing in a primary care setting by integrating Lemonaid Health’s telemedicine and prescription drug delivery services with 23andMe’s personalized genetics services. 23andMe also plans to educate Lemonaid’s physicians on using its genetic reports for patient care. Lemonaid's CEO Paul Johnson will join 23andMe as the general manager of its consumer operations.
In August 2024, the company planned to launch a GLP-1 weight loss telehealth membership by the end of the month. The service would enable members to be prescribed and receive brand-name or compounded semaglutide medications. The new offering would allow customers to access weight loss management services, fitting into the company's strategy of delivering services to improve individual health through preventive actions. The company's parent company, 23andMe, also planned to roll out a large-scale genetic research study to help identify the genetic mechanisms that may drive the efficacy and potential side effects of GLP-1 medications.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.